In order to ensure that you continue to receive information that is of interest from PharmaVentures help us by subscribing. Thank you for your co-operation. New PharmaVentures Report - "Deal Making in the New Healthcare Landscape" Drug delivery experts will learn about the principles of pricing and reimbursement and how to improve deal making and deal valuation in general. In addition, they will get the latest insights into how to incorporate strategic considerations into the assessment of deals and development of products that rely on drug delivery technologies. Read more... The report is due to be published in October 2005 and all pre-publication orders received before 21st October 2005 are eligible for a 10% discount. Order your copy of this report at the special price of £1525/US$2610/€2295 (normally priced £1695/US$2900/€2550). More information on this or any of our other reports Market News and Trends It is interesting to note that of the seventeen drug delivery deals recorded in September, a large proportion relate to vaccine delivery. In order to combat infectious diseases such as Dengue Fever, two deals involve army research institutes and Cyto Pulse Sciences' Easy Vax® DNA vaccine delivery system. In this system, an electric field passes through hundreds of small needles, enabling the delivery of vaccine directly to the immune cells. Another deal relates to the development of a similar electroporation technology; this time directed against the HIV virus, while the US Department of Defence has agreed to fund Inovio Biomedical to develop this technology's potential to fight bioterrorism. Read more... Featured Article An Overview of Paediatric Drug Delivery Children represent a large and vulnerable group of patients, whose needs create a unique set of challenges for drug delivery companies. Dr Catherine Tuleu, the Pfizer paediatric drug delivery lecturer at the University of London's School of Pharmacy, discusses the particular needs of children and their caregivers, the range of formulation and administration technologies that are available and recent moves by the EU to provide drug delivery companies with incentives to develop safe and high-quality products that cause as little stress and discomfort as possible for children and carers alike. Read more... Company Profiles Altea Therapaeutics, Controlled Therapaeutics, Penwest, PSiMedica Drug Delivery Opportunities View all our Drug Delivery Opportunities or alternatively request a password to submit your opportunity online. Featured Opportunity Oral Paclitaxel *NEW* Administrative route - Oral Indication - Cancer Licence code LO-0905-01 Ensure you receive your copy of the Drug Delivery Companies Report Spring / Summer 2006 For deal makers actively assessing drug delivery technology receiving your complimentary copy is a must. The DDCR blends high-quality articles covering the latest drug developments in conjunction with concise profiles of companies active in specific technology areas. Apply to receive the next edition of the DDCR Find out more about promoting your company
Drug Delivery E-News is produced by PharmaVentures Intelligence, part of PharmaVentures - a leading results driven organisation assisting pharmaceutical and biotechnology companies worldwide in all aspects of deal making. Comprising two specialist areas - PharmaVentures Consulting and PharmaVentures Intelligence, we work with clients to drive greater value from their deals. If you do not wish to receive DDCR E-News in future, please e-mail ddcr@pharmamail.biz with the words UNSUBSCRIBE as the subject. If you do not wish to receive other e-mail communications from PharmaVentures or selected third parties, please e-mail ddcr@pharmamail.biz with REMOVE as the subject. For more details contact Paul Sanders, Product Manager, PharmaVentures Ltd, Magdalen Centre, Oxford Science Park, Oxford OX4 4GA, UK. Tel: +44 (0) 1865 784 177 Fax: +44 (0) 1865 784 178 E-mail enquiries@ddcr.com www.ddcr.com